Mazda Biria is a Cardiology physician affiliated with The University of Kansas Health System. OpenAlex indexes 38 publications with 488 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9119 W 74th St Ste 350
Merriam, KS 662042268
Telephone
913-632-9400Provider last certified this registry record 19 Feb 2025.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
32 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year202522 payments
- BIOTRONIK INC.Program year20256 payments
- Biosense Webster, Inc.Program year202513 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
68.8%Beta blocker19.1%Metoprolol Succinate51%Carvedilol25%Metoprolol Tartrate16%Sotalol7%Bisoprolol Fumarate2%Part D<11 patientsCalcium channel blocker11.7%Diltiazem 24hr Er (Cd)47%Amlodipine Besylate34%Diltiazem 24hr Er (Xr)5%Diltiazem 24hr Er4%Dilt-Xr4%Cartia Xt4%Diltiazem Hcl3%Part D<11 patients+ 14 more classes in this area
Blood & clotting
26.8%Factor Xa inhibitor22.4%Eliquis78%Xarelto22%Part D≥157 patientsVitamin K antagonist2%Warfarin Sodium100%Part D≥27 patients+ 2 more classes in this area
Metabolism & gastrointestinal
3.7%SGLT2 inhibitor1.7%Jardiance55%Farxiga45%Part D<11 patientsPotassium supplement1.6%Potassium Chloride100%Part D≥22 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Under-Utilization of Implantable Cardioverter Defibrillators in Patients with Heart Failure - The Current State of Sudden Cardiac Death Prophylaxis
Indian Pacing and Electrophysiology Journal
2015 - Elevated brain natriuretic peptide level in patients undergoing atrial fibrillation ablation: is it a predictor of failed ablation or a mere function of atrial rhythm and rate at a point in time?
Journal of Interventional Cardiac Electrophysiology
2014
Similar KOLs
Other experts from the same institution or the same specialty.
Marilyn Rymer, MD
The University of Kansas Health System
Winston Dunn, MD
The University of Kansas Health System
Ryan Taylor, MD
The University of Kansas Health System
Clinton Humphrey, MD
The University of Kansas Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”